Compare Circle Internet Group Inc. Class A Common Stock (CRCL) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Circle Internet Group Inc. Class A Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Circle Internet Group Inc. Class A Common Stock trades at $86.66 (market cap $20.52B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.92 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Circle Internet Group Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Circle Internet Group Inc. Class A Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| CRCL | RPRX | |
|---|---|---|
Market Cap | $20.52B | $25.27B |
Volume | 9,813,610 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $150.48 | $63.96 |
52-Week Low | $50.23 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $19.03B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Circle Internet Group Inc. Class A Common Stock
Circle Internet Group provides internet financial infrastructure centered on its stablecoin network. Its business includes stablecoins, blockchain infrastructure for developers, digital-asset services, and payment applications.
Read more on CRCL →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
